Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Research & Development (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Research & Development for 15 consecutive years, with $81.1 million as the latest value for Q1 2026.

  • For Q1 2026, Research & Development rose 11.55% year-over-year to $81.1 million; the TTM value through Mar 2026 reached $347.9 million, up 13.93%, while the annual FY2025 figure was $339.5 million, 12.7% up from the prior year.
  • Research & Development hit $81.1 million in Q1 2026 for Agios Pharmaceuticals, down from $88.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $91.9 million in Q2 2025 and bottomed at $65.0 million in Q3 2022.
  • Average Research & Development over 5 years is $76.3 million, with a median of $74.5 million recorded in 2022.
  • Year-over-year, Research & Development increased 25.98% in 2023 and then decreased 11.47% in 2024.
  • Agios Pharmaceuticals' Research & Development stood at $70.3 million in 2022, then increased by 10.23% to $77.5 million in 2023, then rose by 6.87% to $82.8 million in 2024, then increased by 6.33% to $88.1 million in 2025, then dropped by 7.85% to $81.1 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $81.1 million, $88.1 million, and $86.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.